Paul de Potocki



Born 1962. Active in the company since 2021. Paul de Potocki has more than 25 years of experience in international corporate leadership, commercial operations, business and corporate development and financial management in both public and private life sciences companies. He is a former President and Chief Executive Officer of listed companies Diagenic and Aerocrine and has also served as Global Vice President of Commercial Operations at Biovitrum, FreseniusKabi and Pharmacia & Upjohn. Mr. de Potocki currently serves as Chairman of the Board of Asarina Pharma and Board Director of Palette Life Sciences. He holds an MSc from the Royal Institute of Technology in Stockholm and an MBA from the London School of Economics. Shareholding: 0 shares and 290 135 employee stock options.

Pirkko Tamsen



Born 1959. Active in the company since 2020. PhD, 30 years of experience in the pharmaceutical industry including CEO of several SME and CRO companies as well as experience from large pharmaceutical companies Astra and Kabi. Previous board positions include Alzecure Pharma AB and Örebro University Holding AB.
Shareholding: 229 456 shares.

Mark Beveridge



Born 1978. Active in the company since 2020. B. Com, GradDipCA. More than 15 years of experience in finance and accounting, VP Finance Moberg Pharma, advisor in accounting, insurance and auditing, primarily at Crowe Horwath and Visma Services. Independent consultant within financial control, transaction consultancy and implementation of business systems.
Shareholding: 45 144 shares and 24 000 employee stock options.

Markus Jerling



Born 1952. Active in the company since 2021. Legal physician, specialist and PhD in clinical pharmacology. Has worked in several specialties including anesthesia. International and broad experience of clinical development in all development phases from both AstraZeneca and companies in Sweden and the USA. Previous positions include Medical Director and Head of Clinical Pharmacology, Global Drug Surveillance, VP of Clinical Research, CMO. Shareholding: 0 shares and 24 000 employee stock options.